B Cell Induction in Pediatric Lung Transplantation



Status:Active, not recruiting
Conditions:Hospital
Therapuetic Areas:Other
Healthy:No
Age Range:Any - 21
Updated:11/3/2018
Start Date:January 22, 2015
End Date:January 2020

Use our guide to learn which trials are right for you!

B Cell Targeted Induction to Improve Outcomes in Pediatric Lung Transplantation (CTOTC-08)

In this study, doctors are trying to see if a study drug called rituximab (Rituxan®) will
lower the number of B cells in the body. Doctors are also trying to see if decreasing B cells
with rituximab (Rituxan®) can prevent injury to the transplanted lung. This treatment has
been studied in other types of solid organ transplants.

Patients who receive a lung transplant are at risk for rejection of the transplanted lung(s).
Rejection occurs when the new lung triggers the body's defense (immune) system. When the
immune system is triggered special cells are sent out to destroy the new lung and eventually
the lung may not be able to function as it should. These special cells include B cells. B
cells are an important part of the immune system and help the body fight infection. One way B
cells fight infection is by producing antibodies. B cells and the antibodies they produce are
involved in some kinds of rejection after organ transplantation.

Inclusion Criteria:

Enrollment:

1. Subject and/or parent guardian must be able to understand and provide informed
consent;

2. Candidate for a primary lung transplant (listed for lung transplant);

3. Female and male subjects with reproductive potential must agree to use FDA approved
methods of birth control for 12-months after completion of treatment.

4. Adequate bone marrow functions based on the following criteria:

- Absolute neutrophil count (ANC): >1000mm^3

- Platelets: >100,000/mm^3

- Hemoglobin: >7 gm/dL

- AST or ALT< 2x Upper Limit of Normal unless related to primary disease

Randomization:

Individuals who meet all of the following criteria are eligible for randomization:

1. Serum IgG immunoglobulin level greater than lower level of normal for age based on
local laboratory ranges or 400mg/dL within 90 days prior to randomization;

2. Female subjects of childbearing potential must have a negative pregnancy test within 4
hours of transplant;

3. Negative for Hepatitis B infection (if at time of transplant, participant does not
exhibit effective immunization, the participant should be re-tested).

Exclusion Criteria:

Enrollment:

Individuals who meet any of these criteria are not eligible for enrollment as study
participants:

1. Inability or unwillingness of a participant to give written informed consent or comply
with study protocol;

2. Multi-organ transplant;

3. Previous treatment with rituximab (Rituxan®);

4. History of severe allergic anaphylactic reactions to humanized or murine monoclonal
antibodies;

5. History of severe reaction to previous therapy with intravenous immunoglobulin (IVIG);

6. History of Burkholderia cenocepacia;

7. History of anti-CD20 therapy;

8. Persistent hypogammaglobulinemia (IgG < lower level of normal for age based on local
laboratory ranges or 400 gm/dL for >2 months) and/or IVIG replacement therapy;

9. Positive blood culture, sepsis or other disease process with hemodynamic instability
at time of enrollment;

10. Any history of serologic positivity to HIV, HBsAg, HBcAb and HCV Ab;

11. History of malignancy less than 2 years in remission of malignancy (any history of
adequately treated in-situ cervical carcinoma, or adequately treated basal or squamous
cell carcinoma of the skin will be permitted);

12. Any condition, including psychiatric disorders, that in the opinion of the
investigator would interfere with the subject's ability to comply with study
requirements;

13. Participation in another investigational trial within 4 weeks of enrollment;

14. Currently lactating or plans to become pregnant during the timeframe of the study
follow-up period;

15. Past or current medical problems or findings from physical examination or laboratory
testing that are not listed above, which, in the opinion of the investigator, may pose
additional risks from participation in the study, may interfere with the participant's
ability to comply with study requirements or that may impact the quality or
interpretation of the data obtained from the study.

Randomization:

Individuals who meet any of these criteria are not eligible for randomization:

1. Use of an induction agent other than Thymoglobulin®;

2. Renal insufficiency requiring hemodialysis or ultrafiltration;

3. Inability to obtain intravenous access;

4. Positive blood culture, sepsis or other disease process with hemodynamic instability
at time of transplant;

5. Use of investigational agent(s) within 5 half-lives of the investigational drug or 4
weeks, whichever is longer;

6. Receipt of a MMR vaccine within 30 days prior to randomization;

7. Any condition that, in the opinion of the investigator, would interfere with the
subject's ability to comply with study requirements.
We found this trial at
7
sites
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Principal Investigator: Marc Schecter, MD
Phone: 513-803-5191
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
700 Childrens Drive
Columbus, Ohio 43205
(616) 722-2000
Principal Investigator: Don Hayes, MD
Phone: 614-722-6359
Nationwide Children's Hospital At Nationwide Children’s, we are creating the future of pediatric health care....
?
mi
from
Columbus, OH
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
 215-590-1000
Principal Investigator: Samuel Goldfarb, MD
Phone: 267-426-7161
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Boston, Massachusetts 02115
Principal Investigator: Gary Visner, MD
Phone: 617-355-6665
?
mi
from
Boston, MA
Click here to add this to my saved trials
6621 Fannin St
Houston, Texas 77030
(832) 824-1000
Principal Investigator: Ernestina Melicoff-Portillo, MD
Phone: 832-826-0127
Texas Children's Hospital Texas Children's Hospital, located in Houston, Texas, is a not-for-profit organization whose...
?
mi
from
Houston, TX
Click here to add this to my saved trials
Palo Alto, California 94304
Principal Investigator: Carol Conrad, MD
Phone: 650-736-0644
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: Stuart Sweet, MD, PhD
Phone: 314-747-0791
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials